secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0001193125-23-081485
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics reports FY2022 net loss of $48.6M; cash runway into H2 2025
--------------------------------------------------------------------------------

- Net loss $48.6M vs $36.8M in 2021; loss per share $1.58.
- Cash and securities $107.1M at Dec 31, 2022, down from $147.6M.
- IND submitted for lead candidate SNS-101 (VISTA-blocking antibody) in March 2023.
- New collaborations with Regeneron, NCI, and WashU to support SNS-101 development.
- Expects to select candidates for SNS-102 and SNS-103 in 2023; cash runway into H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312523081485/0001193125-23-081485-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312523081485/d466084d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-081485

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer